Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing

• Published in: Journal of the neurological sciences Vol. 453; p. 120811
• Main Authors: Ihara, Keiko, Ohtani, Seiya, Watanabe, Narumi, Takahashi, Nobuyuki, Miyazaki, Naoki, Takemura, Ryo, Hori, Satoko, Nakahara, Jin, Takizawa, Tsubasa
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.10.2023
• Subjects: Antibodies, Monoclonal - adverse effects; Calcitonin Gene-Related Peptide; CGRP; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fremanezumab; Galcanezumab; Hospitals, University; Humans; Injection Site Reaction; Migraine; Migraine Disorders; Neurology; Real-world; Retrospective Studies; Switch; Treatment Outcome; RR; Fremanezumab; FH; MMD; Migraine; CI; Real-world; MOH; MHD; EM; Galcanezumab; CM; NRS; Switch; AMD; CGRP; CGRPmAb; BMI; anti-calcitonin gene-related peptide monoclonal antibody; monthly migraine days; monthly headache days; numerical rating scale; International Classification of Headache Disorders, 3rd edition; chronic migraine; ICHD-3; responder rate; body mass index; monthly acute medication days; calcitonin gene-related peptide; medication overuse headache; episodic migraine; family history; confidence interval

Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) have dramatically changed preventive treatment options for patients with migraine. Although there is emerging real-world evidence on the use of CGRPmAbs globally, the change in efficacy and safety after switching between CGRPmAbs...